Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230122 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3478006 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04230122: Clinical Trial Phase 1 study, sponsored by Eli Lilly and Company.
NCT04230122 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230122, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.
Primary Outcome
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
Interventions
- DRUG Placebo - IV
- DRUG Placebo - SC
- DRUG LY3478006 - IV
- DRUG LY3478006 - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2020-06-04 |
| Phase | Phase 1 |
Why NCT04230122 stopped before completion
NCT04230122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo - IV is the first listed.
NCT04230122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04230122 about?
NCT04230122 is a clinical study titled "A Study of LY3478006 in Healthy Participants". The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. F...
What is the current status of trial NCT04230122?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-02-17. Estimated completion is 2020-06-04.
What interventions are being tested in trial NCT04230122?
The interventions under investigation include: Placebo - IV (DRUG), Placebo - SC (DRUG), LY3478006 - IV (DRUG), LY3478006 - SC (DRUG).
Who is sponsoring clinical trial NCT04230122?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04230122's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI